New infrared sensor extracts amlyloid-beta from blood for early detection of Alzheimer’s.

A major problem of Alzheimer’s disease diagnosis is by the time the first clinical symptoms appear, massive irreversible damage to the brain has already occurred. At that point, symptomatic treatment is the only available option. To have a drug that can significantly inhibit the progress of the disease, blood tests are needed to detect Alzheimer’s in its pre-dementia stages. By applying such drugs at an … Continue reading New infrared sensor extracts amlyloid-beta from blood for early detection of Alzheimer’s.